Profile Photo
Per H. Basse,
M.D., Ph.D., D.M.Sci.

contact

Office: G.17a HCC

Lab: HCC

Phone: 412.623.3236

Fax: 412.623.1119

Email: basse@imap.pitt.edu

Website:

education

M.D. - University of Aarhus (1984)

Ph.D. - University of Aarhus (1992)

D.M.Sci. - University of Aarhus (1996)

academic affiliation

Associate Professor, Department of Immunology, School of Medicine, University of Pittsburgh

Member, University of Pittsburgh Cancer Institute

research interest

Natural killer and T cell traffic in vivo

Tumor infiltration by immune effector cells

NK cell and dendritic cell interactions

Ex vivo production of highly cytotoxic NK cells

Adoptive transfer of NK cells and other anti-cancer effector cells

Use of tumor-seeking NK cells for the delivery of anti-cancer agents selectively to tumor sites

Dietary products and NK cell activity

Metastasis formation and resistance to immune cell infiltration

lab members

Research Assistant Professor
Jae Wynn

Research Specialists
Lisa Bailey
Lyubov Kublo

Medical Student
Michael Cosimini

grant support

Title: Integrating NK and DC into Cancer Therapy
Agency: NIH
Type: Project (in P01 - PI: Michael T. Lotze)
Role: Project leader
Funding Period: 2005-2011


Title: Augmentation of NK cell-mediated anti-cancer activity by dietary BITC
Agency: NIH
Type: R21
Role: PI
Funding Period: 2009-2011


Title: Directing Tumor Specific T cells to Tumors
Agency: NIH
Type: P01 (PI: Pawel Kalinski)
Role: Co-investigator
Funding Period: 2009-2013


Title: Lanthanide Containing ZnS Nanoaparticles
Agency: NIH
Type: R21 (PI: David Waldeck)
Role: Co-investigator
Funding Period: 2009-2010

About Research

Our main goal is to develop an effective treatment of cancer based on immune cells. We study how immune effector cells, in particular natural killer (NK) cells, traffic in the body and how they are able to infiltrate and kill solid tumors. We are also exploring methods by which we can "arm" the tumor-seeking NK cells, so they can bring anti-cancer agents selectively to tumor sites. Since adoptively transferred, IL-2-activated NK cells (called A-NK cells) infiltrate some, but not all metastases, we are investigating the process of metastasis to determine why some metastases develop a phenotype which is fairly resistant to infiltration by A-NK cells.

Selected Publications

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, & Basse PH. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. J Liposome Res. In press.

Yang Q, Larsen SK, Mi Z, Robbins PD, Basse PH. PTD-mediated loading of tumor-seeking lymphocytes with prodrug-activating enzymes. AAPS J 2008;10:614-21.

Goding S, Yang Q, Knudsen KB, Potter DM, Basse PH: Cytokine gene therapy using adenovirally transduced, tumor-seeking A-NK cells. Human Gene Therapy, 2007;18:701-711

Goding SR, Yang Q, Mi Z, Robbins PD, Basse PH. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells. Cancer Gene Therapy. Cancer Gene Ther 2007;14:441-450.

Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P, Nannmark U, Hokland ME, Basse PH. Morphological appearance, content of extracellular matrix, and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells. Cancer Immunol Immunother 2006;55(6):699-707.

View Complete Publications Listing